Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Nov 2 - Nov 7
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
Use in a formulation within 3 - 6 weeks after opening to ensure effectiveness
Not intended for human therapeutic, diagnostic, or clinical applications
Book Online or Call Us Follow the link below to book your treatment online
Melittin restores proteasome function in an animal model of ALS
3cg are the simple linear regression lines (Extended Data Table 2)
US$ 24.43
US$ 22.61
US$ 24.66
